Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives

ObjectiveThe objective of this study is to conduct a bibliometric analysis on examining the current condition, areas of interest, and rising trends of immunotherapy for osteosarcoma (ITFOS), as well as its importance in associated research domains.MethodsAn extensive collection of academic papers on...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yunxiang Hu, Rui Yang, Shuai Ni, Zefeng Song
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	osteosarcoma immune function immunotherapy immune checkpoint inhibitor targeted therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1485053/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics
by: BingBing Li, et al.
Published: (2025-02-01)

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
by: Sophia Kreft, et al.
Published: (2025-01-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer
by: Benchao Zheng, et al.
Published: (2025-04-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
by: Zongfu Pan, et al.
Published: (2025-02-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)

Profile of STING agonist and inhibitor research: a bibliometric analysis
by: Xuemei Wang, et al.
Published: (2025-02-01)

Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives
by: Dong Luo, et al.
Published: (2025-02-01)

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
by: Jumin Huang, et al.
Published: (2025-02-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
by: Ayaka Kawaguchi, et al.
Published: (2025-03-01)

Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study
by: Biling Gan, et al.
Published: (2025-02-01)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
by: Yingyi Li, et al.
Published: (2025-02-01)

Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy
by: Yonghua Cai, et al.
Published: (2025-02-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

OSTEOSARCOMA HAS NOT BECOME ATTENTION TO SOCIETY PROFILE OF OSTEOSARCOMA PATIENTS AT DR. SOETOMO GENERAL HOSPITAL SURABAYA "A RETROSPECTIVE STUDY”
by: Ferdiansyah Mahyudin, et al.
Published: (2019-12-01)

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification
by: Liang Zheng, et al.
Published: (2024-09-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy
by: Minfeng Yang, et al.
Published: (2025-02-01)

Editorial: Immunity and pulmonary vascular diseases: challenges, advances and future perspectives
by: Qi Jin, et al.
Published: (2025-02-01)

Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report
by: Tomoyuki Otsuka, et al.
Published: (2025-02-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01)

Comprehensive analysis of α2,3-sialyltransferases as prognostic biomarkers and immunotherapy targets in kidney renal clear cell carcinoma
by: Yuli Jian, et al.
Published: (2025-02-01)

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors
by: Yan Li, et al.
Published: (2025-02-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01)

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study
by: Keiichiro Suminaga, et al.
Published: (2025-02-01)

ANALYSIS OF IMMUNITY IN OSTEOSARCOMA AS A BASIS FOR DEVELOPMENT FOLLOWING THERAPY
by: Ferdiansyah Mahyudin, et al.
Published: (2019-12-01)

Integral invariant manifold method applied to a mathematical model of osteosarcoma
by: Ophir Nave
Published: (2025-03-01)

Small cell osteosarcoma in gnathic bones in the maxilla: case report in a pediatric patient
by: Tayná Souza Gomes da Silva, et al.
Published: (2025-01-01)

Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
by: Yuanyuan Wang, et al.
Published: (2025-02-01)

Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice
by: Yuanyuan Wang, et al.
Published: (2025-02-01)